Usefulness of osteopontin (OPN) determinations in ovarian cancer patients who underwent first-line chemotherapy;Przydatność oznaczeń stężenia osteopontyny (OPN) u chorych na raka jajnika poddanych chemioterapii I rzutu

Ginekologia Polska

Volumn 82, Issue 12, 2011, Pages 911-917

  Mrochem Kwarciak, Jolanta ^a   Mrochen Domin, Izolda ^a   Wojcieszek, Andrzej ^a   Deja, Regina ^a   Chmura, Aleksandra ^a   Masłyk, Barbara ^a   Nowara, Elzbieta ^a   Kaleta, Beata ^a   Kołosza, Zofia ^a   Wiesława, Bartnik ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Ca 125; First line chemotherapy; Osteopontin; Ovarian cancer

Indexed keywords

CA 125 ANTIGEN; OSTEOPONTIN; SPP1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD; EVALUATION; FEMALE; HUMAN; MIDDLE AGED; OVARY TUMOR; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; FEMALE; HUMANS; MIDDLE AGED; OSTEOPONTIN; OVARIAN NEOPLASMS; REFERENCE VALUES; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84859413085     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Bast R, Badgwell D, Lu Z, [et al.]. New tumor markers: CA125 and beyond. Int J Gynecol Cancer 2005, 15, 274-281.
2. Bast R, Knapp R. Use of the CA 125 antigen in diagnosis and monitoring of ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol, 1985, 19, 354-356.
3. Bergmann J, Bidart J, George M, [et al.]. Elevation of CA 125 in patients with benign and malignant ascites. Cancer.1987, 59,:213-217.
4. Ziółkowska-Seta I, Drabik M, Lindner B, Pietrzak K. Markery nowotworowe-przydatność w diagnostyce i monitorowaniu leczenia guzów jajnika. Onkol Pol. 2001, 4, 147-150.
5. Bast R. Status of tumor markers in ovarian cancer screening. J Clin Oncol. 2003, 21. 200-205.
6. Van Dalen A, Favier J, Burges A, [et al.]. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol Oncol. 2000, 79, 444-450.
7. Rustin G, van der Burg M, Berek J. Advanced ovarian cancer. Tumour markers. Ann Oncol. 1993, 4, 71-77.
8. Zieliński J, Krzakowski M. Nowotwory złośliwe narza{ogonek}du płciowego kobiety. W: Onkologia kliniczna. Red. Krzakowski M. Warszawa: Wydawnictwo Borgis, 2006, 943-999.
9. Rustin G, Quinn M, Thigpen T, [et al.]. Re. New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst. 2004, 96, 487-488.
10. Chakraborty G, Jain S, Behera R, [et al.]. The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med. 2006, 6:, 19-30.
11. El-Tanani M, Campbell F, Kurisetty V, [et al.]. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev. 2006, 17, 463-474.
12. Allan A, George R, Vantyghem S, [et al.]. Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol. 2006, 69, 233-246.
13. Bramwell V, Doig G, Tuck A, [et al.]. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res. 2006, 2, 3337-3343.
14. Higashiyama M, Ito T, Tanaka E, Shimada Y. Prognostic significance of osteopontin expression in human gastric carcinoma. Ann Surg Oncol. 2007,14,3419-3427.
15. Cho H, Hong S, Oh Y, [et al.]. Clinical significance of osteopontin expression in cervical cancer. J Cancer Res Clin Oncol. 2008, 134, 909-917.
16. Visintin I, Feng Z, Longton G. Diagnostic marker for early detection of ovarian cancer. Clin Cancer Res. 2008, 14, 1065-1071.
17. Bao L, Sakaguchi H, Fujimoto J, Tamaya T. Osteopontin in metastatic lesions as a prognostic marker in ovarian cancers. J Biomed Sci. 2007, 14, 373-381.
18. Schorge J, Drake R, Lee H, [et al.]. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin Cancer Res. 2004, 10, 3474-3478.
19. Spentzos D, Levine D, Ramoni M, [et al.]. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol.2004, 22, 4700-4710.